Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Proc Natl Acad Sci U S A
2001 Oct 23;9822:12438-43. doi: 10.1073/pnas.211280698.
Show Gene links
Show Anatomy links
Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells.
Kanovsky M
,
Raffo A
,
Drew L
,
Rosal R
,
Do T
,
Friedman FK
,
Rubinstein P
,
Visser J
,
Robinson R
,
Brandt-Rauf PW
,
Michl J
,
Fine RL
,
Pincus MR
.
???displayArticle.abstract???
We have synthesized three peptides from the mdm-2 binding domain of human p53, residues 12-26 (PPLSQETFSDLWKLL), residues 12-20, and 17-26. To enable transport of the peptides across the cell membrane and at the same time to maximize the active mdm-2 binding alpha-helical conformation for these peptides, each was attached at its carboxyl terminus to the penetratin sequence, KKWKMRRNQFWVKVQRG, that contains many positively charged residues that stabilize an alpha-helix when present on its carboxyl terminal end. All three peptides were cytotoxic to human cancer cells in culture, whereas a control, unrelated peptide attached to the same penetratin sequence had no effect on these cell lines. The same three cytotoxic peptides had no effect on the growth of normal cells, including human cord blood-derived stem cells. These peptides were as effective in causing cell death in p53-null cancer cells as in those having mutant or normal p53. Peptide-induced cell death is not accompanied by expression of apoptosis-associated proteins such as Bax and waf(p21). Based on these findings, we conclude that the antiproliferative effects of these p53-derived peptides are not completely dependent on p53 activity and may prove useful as general anticancer agents.
Amar,
Selective inhibition of oncogenic ras-p21 in vivo by agents that block its interaction with jun-N-kinase (JNK) and jun proteins. Implications for the design of selective chemotherapeutic agents.
1997, Pubmed,
Xenbase
Amar,
Selective inhibition of oncogenic ras-p21 in vivo by agents that block its interaction with jun-N-kinase (JNK) and jun proteins. Implications for the design of selective chemotherapeutic agents.
1997,
Pubmed
,
Xenbase
Clore,
High-resolution structure of the oligomerization domain of p53 by multidimensional NMR.
1994,
Pubmed
Derossi,
Trojan peptides: the penetratin system for intracellular delivery.
1998,
Pubmed
Freedman,
Functions of the MDM2 oncoprotein.
1999,
Pubmed
Fuchs,
MEKK1/JNK signaling stabilizes and activates p53.
1998,
Pubmed
Haffner,
Biochemical properties and biological effects of p53.
1995,
Pubmed
Haupt,
Mdm2 promotes the rapid degradation of p53.
1997,
Pubmed
Karplus,
Hidden Markov models for detecting remote protein homologies.
1998,
Pubmed
Kim,
Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells.
1999,
Pubmed
Kleeff,
Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells.
2000,
Pubmed
Kussie,
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
1996,
Pubmed
Migliaccio,
In vitro differentiation of human granulocyte/macrophage and erythroid progenitors: comparative analysis of the influence of recombinant human erythropoietin, G-CSF, GM-CSF, and IL-3 in serum-supplemented and serum-deprived cultures.
1988,
Pubmed
Müller-Tiemann,
Identification of an additional negative regulatory region for p53 sequence-specific DNA binding.
1998,
Pubmed
Pincus,
ras-p21-induced cell transformation: unique signal transduction pathways and implications for the design of new chemotherapeutic agents.
2000,
Pubmed
Rubinstein,
Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.
1995,
Pubmed
Selivanova,
Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain.
1997,
Pubmed
Vasquez,
Correlation between computed conformational properties of cytochrome c peptides and their antigenicity in a T-lymphocyte proliferation assay.
1987,
Pubmed
Vasquez,
Helix-coil transition theory including long-range electrostatic interactions: application to globular proteins.
1987,
Pubmed
Wasylyk,
p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53.
1999,
Pubmed
Yang,
P63 and P73: P53 mimics, menaces and more.
2000,
Pubmed
Zimmerman,
Influence of local interactions on protein structure. I. Conformational energy studies of N-acetyl-N'-methylamides of Pro-X and X-Pro dipeptides.
1977,
Pubmed